Trial Profile
A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Retosiban (Primary) ; Ketoconazole
- Indications Preterm labour
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 02 Jul 2012 New trial record